MET and non-small cell lung carcinoma: Crizotinib is an oral tyrosine kinase inhibitor (TKI) that targets ALK, mesenchymal epithelial transition factor receptor (MET), and ROS1 tyrosine kinase, and it has become a potent treatment for ROS1-rearranged NSCLC [22,23].